Drug Combination Details
| General Information of the Combination (ID: C69906) | |||||
|---|---|---|---|---|---|
| Name | Sulforaphane NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Osteosarcoma
[ICD-11: 2B51]
|
Investigative | [2] | |||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [3] | |||
|
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. | |||||
| Experiment 2 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ALDH1A1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CD44 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CGA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CXCR4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EPCAM | Molecule Info | |||
| Down-regulation | Expression | GSC | Molecule Info | |||
| Down-regulation | Expression | KDR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MET | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NANOGNB | Molecule Info | |||
| Down-regulation | Expression | OTX2 | Molecule Info | |||
| Down-regulation | Expression | PDX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | POU5F1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PROM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TP63 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
| DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells. | |||||
| Experiment 3 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
| LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
| In-vivo Model | Mice were inoculated with PC-3 cells (1*106 per 100 AL medium) into the dorsolateral lobe of the prostatic capsule. | |||||
| Experimental
Result(s) |
Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. | |||||
| Experiment 4 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. | |||||
| Experiment 5 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SaOS-2 | CVCL_0548 | Osteosarcoma | Homo sapiens | ||
| MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. | |||||
